https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41056 10 mmol/L); occurrence of maternal hypoglycaemia (BGL < 3.8 mmol/l) and incidence of neonatal hypoglycaemia (BGL ≤ 2.5 mmol/L). Analysis was stratified by diabetes type. Results: Overall, Pregnancy-IVI achieved a higher proportion of on-IVI time-in-range (70%, IQR 56-78%) compared to Adult-IVI (52%, IQR 41-69%, p < 0.0001). The duration of critical hyperglycaemia with Pregnancy-IVI was also reduced (2% [IQR 0-7] vs 8% [IQR 4-17], p < 0.0001), without an increase in hypoglycaemia. Glycaemic variability was significantly reduced with Pregnancy-IVI. No difference in the rate of neonatal hypoglycaemia was observed. The Pregnancy-IVI was most effective in women with Type 1 diabetes. Conclusion: The Pregnancy-IVI algorithm is safe and effective when used following betamethasone in type 1 diabetes in pregnancy. Further study of women with type 2 diabetes is required.]]> Wed 22 Nov 2023 16:02:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30973 Wed 19 Jan 2022 15:16:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24093 0.05). Protein loads of 75 and 100 g resulted in lower glycaemic excursions than control in the 60-120 min postprandial interval, but higher excursions in the 180-300 min interval. In comparison with 20 g glucose, the large protein loads resulted in significantly delayed and sustained glucose excursions, commencing at 180 min and continuing to 5 h. Conclusions: Seventy-five grams or more of protein alone significantly increases postprandial glycaemia from 3 to 5 h in people with Type 1 diabetes mellitus using intensive insulin therapy. The glycaemic profiles resulting from high protein loads differ significantly from the excursion from glucose in terms of time to peak glucose and duration of the glycaemic excursion. This research supports recommendations for insulin dosing for large amounts of protein.]]> Wed 11 Apr 2018 17:03:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49963 Tue 20 Jun 2023 14:36:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25825 30 years, family history of diabetes, pre-pregnancy obesity (BMI ≥30kg/m²), prior GDM, early diagnosis of GDM (<24 weeks gestation), fasting venous blood glucose level (≥5.3 mmol/l) and HbA_1c at GDM diagnosis ≥5.5% (≥37 mmol/mol). The requirement for MNT+I could be estimated according to the number of predictors present: 85.7-93.1% of women with 6-7 predictors required MNT+I compared with 9.3-14.7% of women with 0-1 predictors. This model predicted the likelihood of several adverse outcomes, including Caesarean delivery, early delivery, large for gestational age and an abnormal postpartum OGTT. The model was validated in a separate clinic population. Conclusions/interpretation: This validated model has been shown to predict therapy type and the likelihood of several adverse perinatal outcomes in women with GDM.]]> Thu 28 Oct 2021 12:35:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49335 Thu 11 May 2023 15:21:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49334 Thu 11 May 2023 15:21:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44790 Mon 24 Oct 2022 09:17:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46124 P < 0.01), after adjusting for confounders, and more often received insulin therapy (47.0% vs. 33.6%; P < 0.0001), with an adjusted odds ratio (aOR) of 1.4 (95% CI 1.1–1.7; P < 0.01). aORs for each 2-kg increment of cEGWG were a 1.3-fold higher use of insulin therapy (95% CI 1.1–1.5; P < 0.001), an 8-unit increase in final daily insulin dose (95% CI 5.4–11.0; P < 0.0001), and a 1.4-fold increase in the rate of delivery of LGA infants (95% CI 1.2–1.7; P < 0.0001). Conclusions: The absence of EGWG and restricting cEGWG in GDM have a mitigating effect on oGTT-based FPG, the risk of having an LGA infant, and insulin requirements.]]> Fri 11 Nov 2022 15:08:06 AEDT ]]>